Agnete Brunsvik Fredriksen
Chief Scientific Officer & Business Development Nykode Therapeutics
Seminars
Thursday 5th March 2026
Precision Therapy: Achieving Precisely Controlled & Safer Immune Tolerance Through Antigen Presenting Cell-Subtype–Specific Delivery
9:30 am
- Engineered vaccine variants that target antigens to defined immune cell subsets, triggering the immune system in distinct directions depending on which APC that receive the antigen
- Tune immune outcomes to drive preferential effects on autoantibodies, regulatory T cells, and effector cells achieving a level of control unmatched in the field
- Compare versions across sophisticated transgenic models to precisely measure cytokine responses in low-frequency cell populations and define disease-specific immune modulation
NEW DATA
